Skip to content

Kaletra monotherapy studies yield conflicting results

Less risk of AIDS for patients with low CD4 cell count and no treatment options who stay on failing therapy

Raltegravir now available for UK patients

Factors affecting HIV therapy choice in women have changed

Defining, and then watching for, treatment failure

EACS: Switching to atazanavir maintains viral suppression, even in patients with protease resistance

EACS: Nevirapine studies highlight new first-line uses

EACS: One in five UK patients remains on failing therapy for over a year

Undetectable viral load is goal for all, together with earlier treatment, say new European treatment guidelines